Key result
New hierarchical framework guides population-specific statin safety labeling for hepatobiliary risk.
Answers are grounded in this paper and cite their sources.
Framework assesses statin safety in populations, indicating tailored labelling might improve outcomes.
Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Table S1: Raw data extracted from CTT Webfigure 2a and 2b for hepatobiliary adverse events. Table S2: Tier 2 analysis: individual statin versus aggregate of all other statins (Bonferroni correction). Table S3: Tier 3 analysis: pairwise comparisons with Benjamini-Hochberg correction. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Leo Tsui (2026) studied Hepatobiliary adverse events associated with statins. Statins vs. Aggregate of all other statins was evaluated on Hepatobiliary adverse events. A hierarchical risk assessment framework was proposed for population-specific statin safety labelling regarding hepatobiliary adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: